SCHEMBL9950280

SCHEMBL9950280

O=Cc1ccccc1CCCC1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CEL P19835 3/20 0.48
CYSLTR2 Q9NS75 1/20 0.43
CYSLTR1 Q9Y271 1/20 0.43
SIGMAR1 Q99720 1/20 0.42
SRC P12931 1/20 0.42
BCHE P06276 3/20 0.40
MCL1 Q07820 1/20 0.38
KDM1A O60341 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
HPGD P15428 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SLC6A4 P31645 1/20 0.37
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
THRB P10828 1/20 0.36
BLM P54132 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9949898 0.95 CEL (0.49) CELCYSLTR2CYSLTR1SIGMAR1SRC
SCHEMBL9480562 0.94 CYSLTR2 (0.49) CELCYSLTR2CYSLTR1SIGMAR1SRC
SCHEMBL9949465 0.90 CEL (0.45) CELCYSLTR2CYSLTR1SIGMAR1SRC
Ethylene SCHEMBL9949868 0.84 CEL (0.37) CELCYSLTR2CYSLTR1SIGMAR1SRC
Ethylene SCHEMBL9950871 0.81 CYSLTR2 (0.40) CELCYSLTR2CYSLTR1SIGMAR1SRC
SCHEMBL9950572 0.80 SRC (0.46) CELSRCHPGDNPC1RAB9A
SCHEMBL9950460 0.76 ALDH1A1 (0.36) SRCNPC1RAB9AMEN1LMNA
SCHEMBL16593849 0.76 CYP1A2 (0.52) CELCYSLTR2CYSLTR1SIGMAR1BCHE
Ethylene SCHEMBL9950628 0.76 SRC (0.37) CELCYSLTR2CYSLTR1SRCBCHE
SCHEMBL14465961 0.75 LMNA (0.52) SIGMAR1SRCMCL1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748078-B2 Cyclic compound, process for preparation thereof, radiation-sensitive composition, and method for formation of resist pattern MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2014-06-10 US disclosed
EP-2476662-A1 CYCLIC COMPOUND, PROCESS FOR PREPARATION THEREOF, RADIATION-SENSITIVE COMPOSITION, AND METHOD FOR FORMATION OF RESIST PATTERN Mitsubishi Gas Chemical Company, Inc. (JP) 2012-07-18 EP disclosed
US-20120164576-A1 CYCLIC COMPOUND, PROCESS FOR PREPARATION THEREOF, RADIATION-SENSITIVE COMPOSITION, AND METHOD FOR FORMATION OF RESIST PATTERN MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120164576-A1 CYCLIC COMPOUND, PROCESS FOR PREPARATION THEREOF, RADIATION-SENSITIVE COMPOSITION, AND METHOD FOR FORMATION OF RESIST PATTERN RAD1, RER1, REV1 CEL 2007/4885CYSLTR2 2022/4885CYSLTR1 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.